白蛋白结合光敏剂能够通过SPARC途径靶向胶质瘤。

IF 11.3 1区 医学 Q1 Medicine Biomaterials Research Pub Date : 2023-03-21 DOI:10.1186/s40824-023-00360-3
Xingshu Li, Jae Sang Oh, Yoonji Lee, Eun Chae Lee, Mengyao Yang, Nahyun Kwon, Tae Won Ha, Dong-Yong Hong, Yena Song, Hyun Kyu Kim, Byung Hoo Song, Sun Choi, Man Ryul Lee, Juyoung Yoon
{"title":"白蛋白结合光敏剂能够通过SPARC途径靶向胶质瘤。","authors":"Xingshu Li,&nbsp;Jae Sang Oh,&nbsp;Yoonji Lee,&nbsp;Eun Chae Lee,&nbsp;Mengyao Yang,&nbsp;Nahyun Kwon,&nbsp;Tae Won Ha,&nbsp;Dong-Yong Hong,&nbsp;Yena Song,&nbsp;Hyun Kyu Kim,&nbsp;Byung Hoo Song,&nbsp;Sun Choi,&nbsp;Man Ryul Lee,&nbsp;Juyoung Yoon","doi":"10.1186/s40824-023-00360-3","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Malignant glioma is among the most lethal and frequently occurring brain tumors, and the average survival period is 15 months. Existing chemotherapy has low tolerance and low blood-brain barrier (BBB) permeability; therefore, the required drug dose cannot be accurately delivered to the tumor site, resulting in an insufficient drug effect.</p><p><strong>Methods: </strong>Herein, we demonstrate a precision photodynamic tumor therapy using a photosensitizer (ZnPcS) capable of binding to albumin in situ, which can increase the permeability of the BBB and accurately target glioma. Albumin-binding ZnPcS was designed to pass through the BBB and bind to secreted protein acidic and rich in cysteine (SPARC), which is abundant in the glioma plasma membrane.</p><p><strong>Results: </strong>When the upper part of a mouse brain was irradiated using a laser (0.2 W cm<sup>- 2</sup>) after transplantation of glioma and injection of ZnPcS, tumor growth was inhibited by approximately 83.6%, and the 50% survival rate of the treatment group increased by 14 days compared to the control group. In glioma with knockout SPARC, the amount of ZnPcS entering the glioma was reduced by 63.1%, indicating that it can target glioma through the SPARC pathway.</p><p><strong>Conclusion: </strong>This study showed that the use of albumin-binding photosensitizers is promising for the treatment of malignant gliomas.</p>","PeriodicalId":9079,"journal":{"name":"Biomaterials Research","volume":null,"pages":null},"PeriodicalIF":11.3000,"publicationDate":"2023-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10031904/pdf/","citationCount":"1","resultStr":"{\"title\":\"Albumin-binding photosensitizer capable of targeting glioma via the SPARC pathway.\",\"authors\":\"Xingshu Li,&nbsp;Jae Sang Oh,&nbsp;Yoonji Lee,&nbsp;Eun Chae Lee,&nbsp;Mengyao Yang,&nbsp;Nahyun Kwon,&nbsp;Tae Won Ha,&nbsp;Dong-Yong Hong,&nbsp;Yena Song,&nbsp;Hyun Kyu Kim,&nbsp;Byung Hoo Song,&nbsp;Sun Choi,&nbsp;Man Ryul Lee,&nbsp;Juyoung Yoon\",\"doi\":\"10.1186/s40824-023-00360-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Malignant glioma is among the most lethal and frequently occurring brain tumors, and the average survival period is 15 months. Existing chemotherapy has low tolerance and low blood-brain barrier (BBB) permeability; therefore, the required drug dose cannot be accurately delivered to the tumor site, resulting in an insufficient drug effect.</p><p><strong>Methods: </strong>Herein, we demonstrate a precision photodynamic tumor therapy using a photosensitizer (ZnPcS) capable of binding to albumin in situ, which can increase the permeability of the BBB and accurately target glioma. Albumin-binding ZnPcS was designed to pass through the BBB and bind to secreted protein acidic and rich in cysteine (SPARC), which is abundant in the glioma plasma membrane.</p><p><strong>Results: </strong>When the upper part of a mouse brain was irradiated using a laser (0.2 W cm<sup>- 2</sup>) after transplantation of glioma and injection of ZnPcS, tumor growth was inhibited by approximately 83.6%, and the 50% survival rate of the treatment group increased by 14 days compared to the control group. In glioma with knockout SPARC, the amount of ZnPcS entering the glioma was reduced by 63.1%, indicating that it can target glioma through the SPARC pathway.</p><p><strong>Conclusion: </strong>This study showed that the use of albumin-binding photosensitizers is promising for the treatment of malignant gliomas.</p>\",\"PeriodicalId\":9079,\"journal\":{\"name\":\"Biomaterials Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":11.3000,\"publicationDate\":\"2023-03-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10031904/pdf/\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biomaterials Research\",\"FirstCategoryId\":\"5\",\"ListUrlMain\":\"https://doi.org/10.1186/s40824-023-00360-3\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomaterials Research","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1186/s40824-023-00360-3","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 1

摘要

背景:恶性胶质瘤是脑肿瘤中最常见、最致命的肿瘤之一,平均生存期为15个月。现有化疗药物耐受性低,血脑屏障(BBB)通透性低;因此,所需的药物剂量不能准确地传递到肿瘤部位,导致药物效果不足。方法:在此,我们展示了一种精确的光动力肿瘤治疗方法,使用一种能够与白蛋白原位结合的光敏剂(ZnPcS),它可以增加血脑屏障的通透性并准确靶向胶质瘤。白蛋白结合型锌细胞通过血脑屏障,与分泌的富含半胱氨酸(SPARC)的酸性蛋白结合,而SPARC在胶质瘤质膜中含量丰富。结果:胶质瘤移植后,用激光(0.2 W cm- 2)照射小鼠脑上半部分并注射ZnPcS,肿瘤生长被抑制约83.6%,治疗组50%存活率较对照组提高14天。在敲除SPARC的胶质瘤中,ZnPcS进入胶质瘤的数量减少了63.1%,表明它可以通过SPARC途径靶向胶质瘤。结论:白蛋白结合光敏剂在恶性胶质瘤的治疗中具有广阔的应用前景。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Albumin-binding photosensitizer capable of targeting glioma via the SPARC pathway.

Background: Malignant glioma is among the most lethal and frequently occurring brain tumors, and the average survival period is 15 months. Existing chemotherapy has low tolerance and low blood-brain barrier (BBB) permeability; therefore, the required drug dose cannot be accurately delivered to the tumor site, resulting in an insufficient drug effect.

Methods: Herein, we demonstrate a precision photodynamic tumor therapy using a photosensitizer (ZnPcS) capable of binding to albumin in situ, which can increase the permeability of the BBB and accurately target glioma. Albumin-binding ZnPcS was designed to pass through the BBB and bind to secreted protein acidic and rich in cysteine (SPARC), which is abundant in the glioma plasma membrane.

Results: When the upper part of a mouse brain was irradiated using a laser (0.2 W cm- 2) after transplantation of glioma and injection of ZnPcS, tumor growth was inhibited by approximately 83.6%, and the 50% survival rate of the treatment group increased by 14 days compared to the control group. In glioma with knockout SPARC, the amount of ZnPcS entering the glioma was reduced by 63.1%, indicating that it can target glioma through the SPARC pathway.

Conclusion: This study showed that the use of albumin-binding photosensitizers is promising for the treatment of malignant gliomas.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Biomaterials Research
Biomaterials Research Medicine-Medicine (miscellaneous)
CiteScore
10.20
自引率
3.50%
发文量
63
审稿时长
30 days
期刊介绍: Biomaterials Research, the official journal of the Korean Society for Biomaterials, is an open-access interdisciplinary publication that focuses on all aspects of biomaterials research. The journal covers a wide range of topics including novel biomaterials, advanced techniques for biomaterial synthesis and fabrication, and their application in biomedical fields. Specific areas of interest include functional biomaterials, drug and gene delivery systems, tissue engineering, nanomedicine, nano/micro-biotechnology, bio-imaging, regenerative medicine, medical devices, 3D printing, and stem cell research. By exploring these research areas, Biomaterials Research aims to provide valuable insights and promote advancements in the biomaterials field.
期刊最新文献
Injectable biomimetic hydrogel constructs for cell-based menopausal hormone therapy with reduced breast cancer potential Targeted H2S-mediated gas therapy with pH-sensitive release property for myocardial ischemia-reperfusion injury by platelet membrane Ultrasound Controllable Release of Proteolysis Targeting Chimeras for Triple Negative Breast Cancer Treatment Multifunctional hydrogels based on γ-polyglutamic acid/polyethyleneimine for hemostasis and wound healing Combining gut microbiota modulation and enzymatic-triggered colonic delivery by prebiotic nanoparticles improves mouse colitis therapy
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1